Nutra Pharma Corp.
Bringing Healthcare Solutions to the World
Nutra Pharma
Drug Discovery
Medical Devices
Investor Relations
Corporate Overview
Drug Development
R&D Pipeline
Nutra Pharma is developing an innovative pipeline of biopharmaceutical products
Signup to receive news and announcements from Nutra Pharma:
First Name:
Last Name:
Infinite Menus, Copyright 2006, OpenCube Inc. All Rights Reserved.

Welcome to Nutra Pharma

Drug Discovery and Medical Devices

Nutra Pharma Corporation operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases.

The company, through its subsidiaries, carries out basic drug discovery research and clinical development, and also seeks strategic licensing partnerships to reduce the risks associated with the drug development process.

Drug Discovery

Currently, Nutra Pharma offers several drug products for sale for the treatment of pain: Cobroxin, the first over-the-counter (OTC) pain reliever clinically proven to treat moderate to severe (Stage 2) chronic pain, Nyloxin and Nyloxin Extra Strength, the only non-narcotic and non-addictive treatment for severe (Stage 3) pain. Both Cobroxin and Nyloxin were developed by Nutra Pharma’s wholly-owned drug discovery subsidiary, ReceptoPharm.

In addition to manufacturing Cobroxin and Nyloxin, ReceptoPharm is also developing proprietary therapeutic protein products primarily for the prevention and treatment of viral and neurological diseases, including Multiple Sclerosis (MS), Adrenomyeloneuropathy (AMN), and Human Immunodeficiency Virus (HIV), and pain in humans. Outside of its role as the drug discovery arm for Nutra Pharma, ReceptoPharm provides contract research services through its ISO class 5 and GMP certified facilities.

Learn More
Medical Devices

The company’s wholly-owned medical devices subsidiary, Designer Diagnostics, engages in the research and development of diagnostic test kits designed to be used for the rapid identification of infectious diseases, such as Nontuberculous Mycobacteria (NTM).

Learn More
Quick Nav
Nyloxin // Chronic Pain Relief
Read about Jeff Gottfurcht, the first rheumatoid arthritis sufferer to conquer Everest, in Musculoskeletal Health a special section of the Washington Post.


Recent News
October 27, 2015 Publishes New SNNLive Video Interview With Nutra Pharma Corporation

October 22, 2015
Nutra Pharma's Rik Deitsch Interviewed by The Life Sciences Report

September 09, 2015
Nutra Pharma To Present at Upcoming Investment Conference

Click here to view a Letter to Shareholders from the Company's CEO, Rik J Deitsch.
Facebook   Twitter
Privacy Policy Code of Ethics